Case of Diffuse Lepromatous Leprosy Associated with “Mycobacterium lepromatosis”\(^\text{\textdagger}\)

Lucio Vera-Cabrera,1,* Wendy G. Escalante-Fuentes,1 Minerva Gomez-Flores,1 Jorge Ocampo-Candiani,1 Philippe Busso,2 Pushpendra Singh,2 and Stewart T. Cole2

Laboratorio Interdisciplinario de Investigación Dermatológica, Servicio de Dermatología, Hospital Universitario, Monterrey, N.L., Mexico,1 and Global Health Institute, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland2

Received 31 August 2011/Returned for modification 25 September 2011/Accepted 9 October 2011

An 86-year-old female patient from northeast Mexico presented with diffuse lepromatous leprosy (DLL). Sequence analysis of four genes (rrs, rpoB, sigA, and hsp65) from the skin biopsy specimen identified “Mycobacterium lepromatosis.” This is the first independent confirmation of a case of DLL due to M. lepromatosis.

CASE REPORT

In 2005, an 86-year-old female with no prior medical history of leprosy was admitted to our hospital due to a 10-day bout of distal cyanosis of the extremities (Fig. 1). Physical examination also showed generalized dermatosis characterized by diffuse infiltration of the skin, predominantly in the face, with thickening of the superciliary region and ears plus an accompanying absence of eyebrows and eyelashes. In the rest of the body, the skin had an atrophic “cigarette paper”-like appearance and diminished or absent body hair. The neurological examination revealed extensive areas of dysesthesia. The areas of diffuse lepromatous leprosy (DLL) associated with Lucio’s phenomenon were characterized by a purpuric appearance, with necrosis and ulceration in some of the areas, leading to sloughing in acral sites such as fingers and toes. A presumptive diagnosis of cryoglobulinemia versus other vasculitis disorders was considered, and laboratory examination showed microcytic hypochromic anemia, thrombocytosis, leukocytosis, and a rheumatoid factor of 80. A skin biopsy was performed and treatment with pentoxifylline initiated. During the first week, the rheumatologist prescribed cyclophosphamide, but the patient did not improve and developed necrosis in areas that were previously cyanotic (Fig. 1). The skin biopsy specimen showed vasculitis with thrombosis and perivascular and periadnexal lymphocytic infiltrates (Fig. 2) as well as numerous acid-fast bacilli, leading to diagnosis of diffuse lepromatous leprosy (DLL) and Lucio’s phenomenon. Treatment with prednisone and multidrug therapy for multibacillary leprosy was initiated. The patient improved after 10 days of treatment, was discharged after 2 weeks in stable condition, but died at home 3 months later of unknown cause.

Leprosy is one of the oldest recorded human afflictions. Depending upon the immune response mounted against the bacilli, the disease presents with a broad clinical spectrum. At one pole are the tuberculoid (TT) patients, with effective T cell-mediated immunity resulting in very low bacterial numbers, while at the other, the lepromatous (LL) patients mount an ineffective humoral response and exhibit a high bacillary load. Other unstable forms, with characteristics between these poles, can also be observed. A particular variation of lepromatous leprosy involving diffuse nonnodular lesions is more frequent in Mexico and the Caribbean than in any other part of the world (2). This variation has been referred to as diffuse lepromatous leprosy (DLL) or Lucio’s phenomenon (6, 11).

All these forms of leprosy have been attributed to various host responses to the causative pathogen, Mycobacterium leprae. However, M. leprae exhibits exceptionally high genetic homogeneity within different strains across the world (3, 7, 8, 10, 13); thus, M. leprae may not account for such a diverse range of clinical manifestations. Recently, Han et al. (4, 5) have established the existence of “Mycobacterium lepromatosis,” a closely related but distinct species, as a causative agent of DLL in two patients of Mexican origin in Arizona, who succumbed to the disease. Those authors have further investigated the existence of M. lepromatosis in leprosy patients in Mexico and have claimed that M. lepromatosis, particularly the DLL form, is the predominant cause of leprosy there (5). However, this observation has not been confirmed independently in other studies involving Mexican leprosy patients (8), and the clinical significance (in magnitude and distribution) of M. lepromatosis as the causative agent of DLL remains uncertain and is even questioned, despite the fact that DLL cases require management (diagnosis, care, and therapy) that is more specific due to the higher morbidity and even mortality associated with them. Here, we present a retrospective report of a case of M. lepromatosis from the year 2005.

During our drug resistance surveillance study of recently archived leprosy biopsy specimens from Monterrey, Mexico, we observed that the specimen (Mx1-22A) from the case presented above gave negative test results for PCR targeting the M. leprae folP1 and gyrA loci. As this specimen was positive for acid-fast bacilli in the skin smear and also exhibited clear signs of DLL, it was tested for the M. leprae-
specific RLEP repetitive sequence, which is always present in 37 copies in the *M. leprae* genome. This PCR gave no amplification, confirming the absence of *M. leprae* DNA, although the sample yielded a product when rpoB primers were used. Upon analysis of the sequences of the rpoB gene flanking the rifampin resistance-determining region (RRDR), there were multiple mismatches with the *M. leprae* sequence but there was 100% identity with the corresponding sequences of *M. lepromatosis* FJ924.

To confirm this identification, partial sequences of three other genes (*hsp65*, *rrs*, and *sigA*) were determined using the primers described by Han et al. (4) together with additional sets of primers that could amplify the *sigA* sequences from both the *M. leprae* and *M. lepromatosis* species (primer pair LepMato-F1 [5'-CCAGGTTCCTCCTGTATC-3'] and LepMato-R1 [5'-AAGCTTCCACCGATGAGC-3'] and primer pair LepMato-F2 [5'-CACCACAGATGAGACGCAC T-3'] and LepMato-R2 [5'-AACGTCGGCGTCCGTTT]).

together covering the initial 900-bp region of *sigA* in *M. leprae* (TN). All the resulting sequences exhibited 100% identity with the *M. lepromatosis* FJ924 sequences available in the GenBank database, which led to the unambiguous identification of sample Mx1-22 as *M. lepromatosis*. To our knowledge, this is the first independent confirmation of the existence of *M. lepromatosis*, and we believe that *M. lepromatosis* is indeed associated with DLL in Mexico, at least in some cases. However, the proportion of such cases remains unknown and requires further investigation. Such a study could also explain the clinical and geographic variations in the disease spectrum (4).

Like *M. leprae*, *M. lepromatosis* cannot be cultured on artificial media; it also shares other features such as an unusually low G+C content for a mycobacterium (57.8%), the presence of pseudogenes, unique AT-rich insertions in the 16S rRNA gene, and identical six-base tandem repeats in *sigA* (4, 5).

Cases of *M. lepromatosis* infection have exhibited much higher morbidity and even mortality rates than cases of *M. leprae*.

FIG. 1. Patient with diffuse lepromatous leprosy, showing the characteristic madarosis and cutaneous lesions (left panel). Initial cyanotic lesions in the hands that evolved to black necrotic lesions, particularly at the fingertips, are shown (right panel).

FIG. 2. Histopathology. (a) Skin biopsy specimen of the cyanotic lesions, showing vasculitis and thromboembolism. (b) Many acid-fast bacilli were seen upon Fite-Faracca staining.
infection (4). Our patient’s case should encourage further efforts to detect *M. lepromatosis* in order to study its association with Lucio’s phenomenon (12) and its transmission and to identify potential reservoirs. This is particularly desirable at a time when histological diagnosis of leprosy is disappearing and PCR-based methods are becoming more common, especially for drug susceptibility testing (1, 9). However, with the exception of direct DNA sequencing of the RRDR, none of the current PCR tests for *M. leprae* detect *M. lepromatosis*, which means that cases of infection by this newly described leprosy bacillus may go undetected, thus jeopardizing patient recovery.

In many drug resistance surveillance programs, there are some cases where even biopsy specimens from smear-positive lepromatous leprosy patients fail to exhibit PCR amplification using *M. leprae*-specific primers; such results are assumed to be due to the presence of *Taq* polymerase inhibitors or of too few bacilli in the specimen analyzed (14). For such PCR-negative leprosy cases, the use of conserved primers capable of amplifying both *M. leprae* and *M. lepromatosis* could be a better choice. In the majority of cases, and especially in paucibacillary and early-stage cases, *M. leprae* DNA is available in limiting amounts (for molecular drug susceptibility testing and genotyping studies). Therefore, it would be ideal to analyze the RRDR of the *rpoB* gene, especially in the *M. leprae* PCR-negative DLL cases where suspicion of *M. lepromatosis* should be considered. The possibility of mixed infections (5) involving both *M. leprae* and *M. lepromatosis* also needs further investigation. The recent advances in next-generation sequencing technologies have removed several constraints concerning cost and the requisite amounts of DNA for whole genome resequencing. Hence, application of the much-awaited comparative genomics of *M. leprae* and *M. lepromatosis* has the potential to elucidate many issues related to their virulence, evolutionary dynamics, and the endemicity of DLL in Mexico.

This work received the financial support of the Fondation Raoul Follereau.

REFERENCES